Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved overall and progression free survival of patients with metastatic breast cancer, but their effect on short and long-term kidney function is unknown. We found that early, mild estimated glomerular filtration rate (eGFR) decline...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Paul E., Strohbehn, Ian A., Moreno, Daiana, Harden, Destiny, Seethapathy, Rituvanthikaa, Sawtell, Rani, Wang, Qiyu, Ouyang, Tianqi, Katz-Agranov, Nurit, Dinulos, James, Wander, Seth A., Gupta, Shruti, Sise, Meghan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439887/
https://www.ncbi.nlm.nih.gov/pubmed/37598278
http://dx.doi.org/10.1038/s41523-023-00576-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439887/
https://www.ncbi.nlm.nih.gov/pubmed/37598278
http://dx.doi.org/10.1038/s41523-023-00576-5

Ejemplares similares